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Introduction
Combination therapy with BRAF and MEK inhibition is
currently in clinical development for the treatment of
BRAF mutated malignant melanoma. BRAF inhibitors
are associated with enhanced antigen-specific T-lympho-
cyte recognition in vivo. Consequently BRAF inhibition
has been proposed as pro-immunogenic and there has
been considerable enthusiasm for combining BRAF inhi-
bition with immunotherapy. MEK inhibitors inhibit ERK
phosphorylation regardless of BRAF mutational status
and have been reported to impair T-lymphocyte and
dendritic cell function. In this study we investigate the
effects on isolated T-lymphocytes and monocyte-derived
dendritic cells (moDCs) of a MEK and BRAF inhibitor
combination currently being evaluated in a randomized
controlled clinical trial.
Experimental design
The effects of a BRAF inhibitor and a MEK inhibitor,
alone and in combination were studied on isolated nor-
mal T-lymphocyte and moDCs. Lymphocyte viability,
together with functional assays including proliferation,
cytokine production and antigen-specific expansion, were
assessed. moDC phenotype in response to lipo-polysac-
charide stimulation was evaluated by flow-cytometry, as
were effects on antigen crosspresentation.
Results
BRAF inhibition did not have an impact on T-lymphocytes
or moDCs, whereas MEK inhibition alone or in combina-
tion with BRAF inhibition suppressed T-lymphocyte pro-
liferation, cytokine production and antigen-specific
expansion. Similarly, moDC cross-presentation was sup-
pressed in association with enhanced maturation following
combined inhibition of MEK and BRAF. However no sig-
nificant decrease in CD4+ or CD8+ T-lymphocyte viability
was observed following kinase inhibition.
Conclusions
MEK inhibition, alone or in combination with BRAF inhi-
bition can suppress immune cell function and further stu-
dies in vivo will be required to evaluate the potential
clinical impact of these findings.
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